New combo therapy aims to shrink tumors in Tough-to-Treat colon cancer

NCT ID NCT07253896

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

Summary

This study is testing a new combination of drugs for people with advanced colorectal cancer that has spread and worsened after their first treatment. The goal is to see if adding an immunotherapy drug (AK104) to standard chemotherapy and targeted therapy can shrink tumors and control the cancer. The study will enroll about 40 patients to evaluate how well the combination works and how safe it is.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAFETY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, Zhejiang, 310000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
the Second Affiliated Hospital of Medical College of Zhejiang University
RECRUITING

Hangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SAFETY